TD Cowen raised the firm’s price target on 10x Genomics (TXG) to $19 from $18 and keeps a Hold rating on the shares. The firm said they posted a Q4 revenue beat and the focus was on the guidance and trends and management tone is improved with the worst of the U.S. A&G pressure likely passed it.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- Neutral on 10x Genomics: Solid Competitive Position but Cautious Spending and Unclear Growth Keep Rating at Hold
- 10x Genomics price target raised to $20 from $15 at Stifel
- 10x Genomics price target raised to $22 from $20 at Canaccord
- Maintaining a Neutral Hold: Solid Q4 Beat but Limited 2026 Growth Visibility and Valuation Upside
- 10x Genomics reports Q4 EPS (13c), consensus (4c)